Pharsight

Drugs that contain Sotorasib

1. Lumakras patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(14 years from now)

US11236091 AMGEN INC Solid state forms
May, 2040

(16 years from now)

US11827635 AMGEN INC Solid state forms
May, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Sep, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026
Orphan Drug Exclusivity(ODE-352) May 28, 2028

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...

Dosage: TABLET;ORAL

More Information on Dosage

LUMAKRAS family patents

Family Patents